+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Sarcoidosis - Pipeline Review, H2 2015

  • ID: 3440626
  • Report
  • September 2015
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Celgene Corporation
  • Novartis AG
  • PharmaIN Corporation
  • MORE
Sarcoidosis - Pipeline Review, H2 2015

Summary

The report ‘Sarcoidosis - Pipeline Review, H2 2015’, provides an overview of the Sarcoidosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Sarcoidosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Sarcoidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sarcoidosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Celgene Corporation
  • Novartis AG
  • PharmaIN Corporation
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Sarcoidosis Overview

Therapeutics Development

Pipeline Products for Sarcoidosis - Overview

Pipeline Products for Sarcoidosis - Comparative Analysis

Sarcoidosis - Therapeutics under Development by Companies

Sarcoidosis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Sarcoidosis - Products under Development by Companies

Sarcoidosis - Companies Involved in Therapeutics Development

Araim Pharmaceuticals Inc.

Celgene Corporation

FirstString Research, Inc.

Novartis AG

PharmaIN Corporation

Sarcoidosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ABS-11 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-220 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cibinetide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eprodisate disodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PGC-VIP - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide for Sarcoidosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sarcoidosis - Recent Pipeline Updates

Sarcoidosis - Dormant Projects

Sarcoidosis - Discontinued Products

Sarcoidosis - Product Development Milestones

Featured News & Press Releases

Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA

Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy

Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring

Oct 10, 2013: Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Sarcoidosis, H2 2015

Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Sarcoidosis - Pipeline by Araim Pharmaceuticals Inc., H2 2015

Sarcoidosis - Pipeline by Celgene Corporation, H2 2015

Sarcoidosis - Pipeline by FirstString Research, Inc., H2 2015

Sarcoidosis - Pipeline by Novartis AG, H2 2015

Sarcoidosis - Pipeline by PharmaIN Corporation, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Sarcoidosis Therapeutics - Recent Pipeline Updates, H2 2015

Sarcoidosis - Dormant Projects, H2 2015

Sarcoidosis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Sarcoidosis, H2 2015

Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 5
Araim Pharmaceuticals Inc.
Celgene Corporation
FirstString Research, Inc.
Novartis AG
PharmaIN Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll